Cargando…
Exploring the efficacy of tumor electric field therapy against glioblastoma: An in vivo and in vitro study
AIMS: Tumor electric fields therapy (TTFields) is emerging as a novel anti‐cancer physiotherapy. Despite recent breakthroughs of TTFields in glioma treatment, the average survival time for glioblastoma patients with TTFields is <2 years, even when used in conjugation with traditional anti‐cancer...
Autores principales: | Wu, Hao, Yang, Lin, Liu, Hanjie, Zhou, Dan, Chen, Dikang, Zheng, Xiaoque, Yang, Hui, Li, Chong, Chang, Jiusheng, Wu, Anhua, Wang, Zhifei, Ren, Nianjun, Lv, Shengqing, Liu, Yuyang, Jia, Muyuan, Lu, Jian, Liu, Hongyu, Sun, Guochen, Liu, Zhixiong, Liu, Jialin, Chen, Ling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611775/ https://www.ncbi.nlm.nih.gov/pubmed/34710276 http://dx.doi.org/10.1111/cns.13750 |
Ejemplares similares
-
Evaluation of a tumor electric field treatment system in a rat model of glioma
por: Wu, Hao, et al.
Publicado: (2020) -
Whole transcriptome and proteome analyses identify potential targets and mechanisms underlying tumor treating fields against glioblastoma
por: Xu, Shengchao, et al.
Publicado: (2022) -
Correction: Whole transcriptome and proteome analyses identify potential targets and mechanisms underlying tumor treating fields against glioblastoma
por: Xu, Shengchao, et al.
Publicado: (2022) -
circMMD reduction following tumor treating fields inhibits glioblastoma progression through FUBP1/FIR/DVL1 and miR-15b-5p/FZD6 signaling
por: Xu, Shengchao, et al.
Publicado: (2023) -
Prospects of antibodies targeting CD47 or CD24 in the treatment of glioblastoma
por: Wu, Hao, et al.
Publicado: (2021)